DGAP-News: UET United Electronic Technology AG releases

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DGAP-News: UET United Electronic Technology AG releases financial figures for operating business for the first quarter 2015

UET United Electronic Technology AG / Key word(s): Quarter Results/Miscellaneous 16.06.2015 17:45 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer / publisher is solely responsible for the content of this announcement. --------------------------------------------------------------------------- - Consolidated revenues amounted to 15.347 mn EUR - Revenue growth of 1.714 mn EUR (without ALBIS Technologies AG) - Increase in profits within the business units SYSTEMS und MANUFACTURING UET United Electronic Technology AG (ISIN: DE000A0LBKW6), Eschborn, releases selected financial figures for the operating business units SYSTEMS, MANUFACTURING and SERVICE for the first quarter of 2015, from January 1st to March 31st 2015. In the period from January to March of the fiscal year 2015, the operating companies and business units in the core business of the UET Group generated consolidated revenues of 15.347 mn EUR. With regard to the companies belonging to the UET Group in the previous year (without ALBIS Technologies AG), a revenue increase of 1.714 mn EUR was achieved compared to the same period of the previous year. The business units SYSTEMS and MANUFACTURING, referring to the companies belonging to the UET Group during the same quarter of the previous year, were able to improve and refine their profits. Excluding consolidation effects, the financial figures are presented as follows: In the business unit SYSTEMS, ELCON Systemtechnik increased its revenues from 7.948 mn EUR to 9.919 mn EUR and, therefore, by 25%. Despite again increased expenses in the field of research and development, the EBITDA could be improved by 0.620 mn EUR to +1.051 mn EUR and the EBIT could be improved to +0.569 mn EUR. Also in the business unit SYSTEMS, ALBIS Technologies AG, which was acquired at the beginning of the year, generated quarterly revenues of 5.879 mn EUR. EBITDA as well as EBIT were negative and amount to -1.163 mn EUR and -1.198 mn EUR respectively in the first three months of the fiscal year. With regard to the time of acquisition, ALBIS Technologies is included in the consolidation of the UET Group as of March 1st 2015, which amounted to a revenue share of 2.053 mn EUR. EBITDA and EBIT for March amounted to -0.444 mn EUR and -0.456 mn EUR respectively. The development of ALBIS' earnings is in line with expectations and already considered with respect to terms of pricing as well as structure. Aiming at increasing growth and revenue, the company is currently being integrated into the business unit SYSTEMS. In the business unit MANUFACTURING, LETRON electronic experienced a decrease in revenues of 27% to 2.105 mn EUR for the first quarter of 2015. With +0.075 mn EUR, the EBITDA was positive but below the previous year's figure by 0.014 mn EUR. With +0.074 mn EUR, the EBIT was also positive but slightly decreased by 0.013 mn EUR. NEWTAL Elektronik & Systeme generated revenues of 2.796 mn EUR and was, therefore, almost at the level of the previous year. Despite almost unchanged revenues, the EBITDA was improved by 0.023 mn EUR to +0.148 mn EUR. The EBIT was increased by 0.025 mn EUR and is now at +0.126 mn EUR. The business unit MANUFACTURING thereby confirmed the positive operative results of the previous quarters. In the business unit SERVICE, SUCONI Service reported revenues of 0.398 mn EUR for the first quarter, which represented a decrease of 21% compared to the same period of the previous year. Both EBITDA and EBIT were negative and amounted to -0.083 mn EUR and thus are below the previous year's level. For the second quarter, we expect an overall decrease in profits. Investments on product and market development have been increased and ALBIS will still contribute a negative profit share. The reported financial figures do not include consolidation effects of existing non operating UET Holding companies. Extended full consolidated financials will be reported within the half-year report 2015. Contact: UET United Electronic Technology AG Frankfurter Straße 80-82 D-65760 Eschborn Sebastian Schubert Tel: + 49 (0) 6196 777755-0 E-Mail: investor@uet-group.com 16.06.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: UET United Electronic Technology AG Frankfurter Straße 80-82 65760 Eschborn Germany Phone: +49 (0)6196-7777550 Fax: +49 (0)6196-7777559 E-mail: investor@uet-group.com Internet: www.uet-group.com ISIN: DE000A0LBKW6 WKN: A0LBKW Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Stuttgart; Open Market (Entry Standard) in Frankfurt End of Announcement DGAP News-Service ---------------------------------------------------------------------------

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 5

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 1

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 3

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 2

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

CAPREIT Welcomes Francine Moore to Board of Trustees

Updated Category News Views 162

CAPREIT Welcomes Francine Moore to Board of Trustees CAPREIT is excited to share that Ms. Francine Moore has been appointed as a new member of its Board of Trustees. This appointment took effect on November 7. Francine is known for her significant experience in the real estate sector, where she has built a remarkable career. Ms. Moore's Impressive Background With over 25...

Continue Reading
Cimpress Sees Target Adjustments Yet Remains Strong – A Deeper Look

Updated Category News Views 95

Cimpress Stock Target Adjustments and Outlook Recently, Truist Securities made notable adjustments to the stock price target for Cimpress N.V. (NASDAQ: CMPR), a recognized leader in mass customization solutions. The new target is now set at $110.00, reduced from the previous $120.00. Despite this adjustment, the firm has reiterated a Buy rating, showcasing confidence in...

Continue Reading
Significant Shift in NICUs: Embracing Prolacta's Innovations

Updated Category News Views 131

Transforming Neonatal Care with Prolacta's Nutritional Innovations Prolacta Offers the Only Nutritional Products Free From Cow Milk and Added Synthetic Ingredients for Extremely Premature Infants in the U.S. In an exciting development for neonatal care, Prolacta Bioscience® has reported that in 2025, the majority of Level III and IV neonatal intensive care units (NICUs)...

Continue Reading
Orchestry Unveils Automated Workspace Solutions for Microsoft 365

Updated Category News Views 127

Orchestry Launches Innovative Workspace Review for Teams and SharePoint Orchestry has introduced a groundbreaking feature that aims to transform the way IT administrators manage collaboration workspaces within Microsoft 365. This new capability, known as Workspace Review, not only automates the maintenance of these workspaces but also enhances security and compliance...

Continue Reading
The Investment Journey of Webster Financial Over Five Years

Updated Category News Views 151

Understanding Webster Financial's Growth Over the Years Webster Financial (NYSE: WBS) has demonstrated remarkable performance in the stock market, consistently outperforming many competitors. Over the past five years, it has achieved an impressive average annual return of 15.04%, surpassing the market by 1.25% annually. This impressive growth reflects the ongoing...

Continue Reading